JP2013538819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538819A5 JP2013538819A5 JP2013529674A JP2013529674A JP2013538819A5 JP 2013538819 A5 JP2013538819 A5 JP 2013538819A5 JP 2013529674 A JP2013529674 A JP 2013529674A JP 2013529674 A JP2013529674 A JP 2013529674A JP 2013538819 A5 JP2013538819 A5 JP 2013538819A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- imaging agent
- lbp
- agent according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012216 imaging agent Substances 0.000 claims description 13
- 239000002738 chelating agent Substances 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 3
- YYLQUHNPNCGKJQ-NHYDCYSISA-N (3R)-3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)[C@@H](O)C(O)=O YYLQUHNPNCGKJQ-NHYDCYSISA-N 0.000 claims description 2
- 108010062877 Bacteriocins Proteins 0.000 claims description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 125000005549 heteroarylene group Chemical group 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 239000012217 radiopharmaceutical Substances 0.000 claims 3
- 229940121896 radiopharmaceutical Drugs 0.000 claims 3
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1016206.3 | 2010-09-27 | ||
| GBGB1016206.3A GB201016206D0 (en) | 2010-09-27 | 2010-09-27 | Apoptosis imaging agents |
| PCT/EP2011/066789 WO2012041862A1 (en) | 2010-09-27 | 2011-09-27 | Apoptosis imaging agents based on lantibiotic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538819A JP2013538819A (ja) | 2013-10-17 |
| JP2013538819A5 true JP2013538819A5 (enExample) | 2014-11-13 |
Family
ID=43128013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529674A Withdrawn JP2013538819A (ja) | 2010-09-27 | 2011-09-27 | ランチビオチックペプチド系アポトーシスイメージング剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130189186A1 (enExample) |
| EP (1) | EP2621545A1 (enExample) |
| JP (1) | JP2013538819A (enExample) |
| KR (1) | KR20130097780A (enExample) |
| CN (1) | CN103118710A (enExample) |
| AU (1) | AU2011310663A1 (enExample) |
| BR (1) | BR112013006536A2 (enExample) |
| CA (1) | CA2810573A1 (enExample) |
| GB (1) | GB201016206D0 (enExample) |
| MX (1) | MX2013003398A (enExample) |
| RU (1) | RU2013113677A (enExample) |
| SG (1) | SG188464A1 (enExample) |
| WO (1) | WO2012041862A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108144073A (zh) * | 2017-12-28 | 2018-06-12 | 中山大学附属第医院 | 靶向磷脂酰乙醇胺的放射性标记三聚乙二醇修饰耐久霉素多肽药物 |
| GB201804835D0 (en) * | 2018-03-26 | 2018-05-09 | Ge Healthcare As | Formulation and method of preparation |
| EP4057002B1 (en) | 2019-11-12 | 2024-08-07 | Ewha University-Industry Collaboration Foundation | Cell imaging composition and cellular material imaging method using same |
| CN113368264B (zh) * | 2020-03-09 | 2022-09-30 | 南方医科大学南方医院 | 放射性标记肉桂霉素，其制备方法及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0105224D0 (en) * | 2001-03-02 | 2001-04-18 | Nycomed Amersham Plc | Improved peptide-chelate conjugates |
| US7034113B2 (en) * | 2002-02-22 | 2006-04-25 | Paradigm Diagnostics, Llc | Bacteriocin-metal complexes in the detection of pathogens and other biological analytes |
| US7879801B2 (en) | 2002-07-15 | 2011-02-01 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| US20060110323A1 (en) | 2004-11-19 | 2006-05-25 | Ming Zhao | Method of imaging cell death in vivo |
| AU2009223677A1 (en) | 2008-03-10 | 2009-09-17 | Mcw Research Foundation, Inc. | 99mTc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical |
-
2010
- 2010-09-27 GB GBGB1016206.3A patent/GB201016206D0/en not_active Ceased
-
2011
- 2011-09-27 CN CN2011800462575A patent/CN103118710A/zh active Pending
- 2011-09-27 BR BR112013006536A patent/BR112013006536A2/pt not_active Application Discontinuation
- 2011-09-27 RU RU2013113677/04A patent/RU2013113677A/ru not_active Application Discontinuation
- 2011-09-27 MX MX2013003398A patent/MX2013003398A/es unknown
- 2011-09-27 WO PCT/EP2011/066789 patent/WO2012041862A1/en not_active Ceased
- 2011-09-27 AU AU2011310663A patent/AU2011310663A1/en not_active Abandoned
- 2011-09-27 US US13/876,187 patent/US20130189186A1/en not_active Abandoned
- 2011-09-27 CA CA2810573A patent/CA2810573A1/en not_active Abandoned
- 2011-09-27 JP JP2013529674A patent/JP2013538819A/ja not_active Withdrawn
- 2011-09-27 EP EP11761385.1A patent/EP2621545A1/en not_active Withdrawn
- 2011-09-27 KR KR1020137010727A patent/KR20130097780A/ko not_active Withdrawn
- 2011-09-27 SG SG2013017306A patent/SG188464A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10016519B2 (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| AU2018352731B2 (en) | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer | |
| CN111182927B (zh) | 用于成像和腔内放射治疗的psma配体 | |
| JP2018076328A5 (enExample) | ||
| JP2020165975A (ja) | 陽電子放出断層撮影用の化合物 | |
| JP7097436B2 (ja) | エバンスブルー誘導体の化学的コンジュゲートおよびそれらの放射線治療剤および造影剤としての使用 | |
| KR102233726B1 (ko) | 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도 | |
| AU2016352491B2 (en) | Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer | |
| US20080267882A1 (en) | Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy | |
| JP2018058847A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 | |
| JP2017518971A (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| JP7184775B2 (ja) | 黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用 | |
| JP2008195715A5 (enExample) | ||
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2018531243A6 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用 | |
| ES2828033T3 (es) | Pautas posológicas de melflufen para el cáncer | |
| RU2013123909A (ru) | Рет-агенты для визуализации апоптоза | |
| JP2013538819A5 (enExample) | ||
| TW202340226A (zh) | 碳酸酐酶ix配位體 | |
| JP2010502585A5 (enExample) | ||
| JP2014500268A5 (enExample) | ||
| TW202416974A (zh) | 標靶細胞外HSP90(eHSP90)之放射性藥物及其用途 | |
| CN116217505A (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| RU2013113677A (ru) | Визуализирующие апоптоз агенты на основе лантибиотических пептидов | |
| EP3011976A1 (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |